TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
Biotec Betaglucans AS
Closing information (x1000 NOK)
| Closing information | 2025/01 | 2024/01 | 2023/01 |
| Turnover |
45,734
|
32,308
|
16,190 |
| Financial expenses |
1,353
|
1,777
|
2,150 |
| Earnings before taxes |
7,696
|
3,417
|
2,359 |
| Total assets |
34,044
|
33,234
|
22,608 |
| Current assets |
19,520
|
25,263
|
19,643 |
| Current liabilities |
16,363
|
19,248
|
9,039 |
| Equity capital |
17,681
|
13,986
|
13,569 |
| - share capital |
1,000
|
1,000
|
1,000 |
Financial ratios
| Fiscal year | 2025/01 | 2024/01 | 2023/01 |
| Solvency |
51.9%
|
42.1%
|
60.0% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
16.8%
|
10.6%
|
14.6% |
| Return on assets (ROA) |
26.6%
|
15.6%
|
19.9% |
| Current ratio |
119.3%
|
131.2%
|
217.3% |
| Return on equity (ROE) |
43.5%
|
24.4%
|
17.4% |
| Change turnover |
13,426
|
16,118
|
-9,711 |
| Change turnover % |
42%
|
100%
|
-37% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2025/01 | 2024/01 | 2023/01 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.